morphine sulphate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 7 Diseases   379 Trials   379 Trials   12426 News 


«12...1516171819202122232425...216217»
  • ||||||||||  morphine sulphate / Generic mfg.
    Reimbursement, Retrospective data, US reimbursement, Journal, Medicaid:  Opioid utilization after orthopaedic trauma hospitalization among Medicaid-insured adults. (Pubmed Central) -  Apr 14, 2024   
    Filled opioid prescriptions were identified from National Drug Codes and converted to morphine milligram equivalents (MME)...There were significant variations in opioid prescribing practices by race, sex, and region. National guidelines for use of opioids and other pain management interventions in adults after trauma hospitalization may help limit practice variation and reduce implicit bias and potential harms in outpatient opioid usage.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal, HEOR:  Healthcare Utilization (HCU) Reduction with High-Frequency (10 kHz) Spinal Cord Stimulation (SCS) Therapy. (Pubmed Central) -  Apr 13, 2024   
    We focused on assessing trends in HCU by measuring opioid consumption in morphine milligram equivalents (MME), as well as monitoring emergency department (ED) and office visits for interventional pain procedures during the 12-month period preceding and following the SCS implant...Furthermore, this is the first and only study evaluating HCU trends with 10 kHz SCS by assessing opioid use, ED visits, and outpatient visits for interventional pain procedures collectively. Preceding studies have individually investigated these outcomes, consistently yielding positive results comparable to our findings.
  • ||||||||||  morphine sulphate / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Cordotomy in Reducing Pain in Patients With Advanced Cancer (clinicaltrials.gov) -  Apr 11, 2024   
    P=N/A,  N=42, Recruiting, 
    Sequential injection of intrathecal opioids and hyperbaric bupivacaine resulted in greater early haemodynamic instability and slightly better postoperative analgesia without any difference in block height or patient satisfaction. Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Challenges of acute pain management in older patients. (Pubmed Central) -  Apr 5, 2024   
    Nevertheless, these modalities can be valuable options for patients where opioid analgesics are contraindicated or when intravenous morphine titration is impractical or contraindicated. Here, we review these concepts, the latest evidence and propose avenues for research.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Tiam1-mediated maladaptive plasticity underlying morphine tolerance and hyperalgesia. (Pubmed Central) -  Apr 5, 2024   
    Furthermore, co-administration of the Tiam1 signaling inhibitor NSC23766 was sufficient to abrogate morphine tolerance in chronic pain management. These findings identify Tiam1-mediated maladaptive plasticity in the spinal nociceptive network as an underlying cause for the development and maintenance of morphine tolerance and OIH and provide a promising therapeutic target to reduce tolerance and prolong morphine use in chronic pain management.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Phosphorescent acyclic cucurbituril solid supramolecular multicolour delayed fluorescence behaviour. (Pubmed Central) -  Apr 5, 2024   
    By virtue of the intrinsic self-crimping configuration of ACB-COOH, organic guests, including fluorescence dyes (Rhodamine B (RhB) and Pyronin Y (PyY)) and a drug molecule (morphine (Mor)), could be fully encapsulated by ACB-COOH to attain energy transfer involving phosphorescent acyclic cucurbituril...As an expansion of phosphorescent acyclic cucurbituril, the host afterglow color can be readily regulated by attaching different aromatic sidewalls. This study develops the fabrication strategies and application scope of a supramolecular phosphorescent host and opens up a new direction for the manufacture of intelligent long-lived luminescent materials.
  • ||||||||||  Exparel (bupivacaine liposome injectable suspension) / Pacira
    Journal:  Reduced Opioid Use Among Patients Who Received Liposomal Bupivacaine Brachial Plexus Block for Total Shoulder Arthroplasty. (Pubmed Central) -  Apr 5, 2024   
    This study develops the fabrication strategies and application scope of a supramolecular phosphorescent host and opens up a new direction for the manufacture of intelligent long-lived luminescent materials. Patients who received an Exparel brachial plexus block had decreased opioid use within the first 24 hours after surgery compared to the ropivacaine group, 9.00
  • ||||||||||  morphine sulphate / Generic mfg.
    Trial completion date, Trial primary completion date:  Ultrasound Guided Femoral Nerve Block (clinicaltrials.gov) -  Apr 4, 2024   
    P=N/A,  N=60, Recruiting, 
    Patients who received an Exparel brachial plexus block had decreased opioid use within the first 24 hours after surgery compared to the ropivacaine group, 9.00 Trial completion date: Dec 2021 --> Dec 2026 | Trial primary completion date: May 2021 --> May 2025
  • ||||||||||  morphine sulphate / Generic mfg., ondansetron intravenous / Generic mfg., dexamethasone injection / Generic mfg.
    Enrollment open:  Bilateral Erector Spinae Plane Block for Postoperative Chronic Pain After Open Heart Surgery (clinicaltrials.gov) -  Apr 2, 2024   
    P=N/A,  N=50, Recruiting, 
    Analysis of RRPs with expanded inclusion criteria should be undertaken to better understand the role of these protocols in patients who undergo revision TKA and THA. Not yet recruiting --> Recruiting
  • ||||||||||  morphine sulphate / Generic mfg., aspirin / Generic mfg.
    Preclinical, Journal:  Evaluation of the antinociceptive activities of natural propolis extract derived from stingless bee Trigona thoracica in mice. (Pubmed Central) -  Apr 1, 2024   
    In the formalin test, the durations of paw licking were significantly reduced at early and late phases in all APE groups with a decrease from 45.1% to 53.3%. : APE from Trigona thoracica, containing p-coumaric acid and caffeic acid, exhibited antinociceptive effects, which supports its potential use in targeting the prevention or reversal of central and peripheral sensitization that may produce clinical pain conditions.
  • ||||||||||  morphine sulphate / Generic mfg.
    Journal:  Unveiling Morphine: A Rapid and Selective Fluorescence Sensor for Forensic and Medical Analysis. (Pubmed Central) -  Apr 1, 2024   
    Consequently, this molecular probe demonstrates a successful application in determining trace amounts of morphine within urine, yielding satisfactory analytical results. The study also explores the effect of several variables on the sensor's response and optimizes the detection of morphine in urine using a response surface methodology with a central composite design.
  • ||||||||||  fentanyl citrate / Generic mfg., morphine sulphate / Generic mfg., dexamethasone injection / Generic mfg.
    Review, Journal:  Caesarean Delivery: A Narrative Review on the Choice of Neuraxially Administered Opioid and Its Implications for the Multimodal Peripartum Pain Concept. (Pubmed Central) -  Apr 1, 2024   
    Long-acting lipophobic opioids (diamorphine and morphine) have a significant analgesic advantage over short-acting lipophilic opioids (sufentanil and fentanyl)...The question remains as to whether a pain concept that is ideally adapted to a neuraxial short-acting opioid shows benefit to a pain concept that is optimally adapted to neuraxial morphine. If long-acting opioids are used, the timing of each additional component of the multimodal analgesia strategy could ideally be adjusted to this longer duration of action.
  • ||||||||||  morphine sulphate / Generic mfg.
    Trial completion date, Adverse events:  Decreased Neuraxial Morphine After Cesarean Delivery (clinicaltrials.gov) -  Apr 1, 2024   
    P1,  N=87, Active, not recruiting, 
    SHNB, as an adjunct to analgesic optimisation, facilitates same-day discharge, which is often limited by severe post-embolisation pain. Trial completion date: Dec 2023 --> Dec 2024
  • ||||||||||  morphine sulphate / Generic mfg., hydromorphone hydrochloride / Generic mfg.
    Journal:  Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone. (Pubmed Central) -  Mar 30, 2024   
    The patient presented with a history of inadequate pain control despite analgesic treatment with oxycodone (morphine milliequivalent [MME] = 22.5)...The patient was subsequently switched to hydromorphone (MME = 16), resulting in improved pain control and fewer side effects...Further PGx testing results led to an overall positive outcome, such as her willingness to participate in physical therapy as a result of improved pain scores. This case highlights the importance of considering individual variability in drug metabolism when prescribing medications, particularly opioids such as oxycodone, to ensure optimal therapeutic outcomes and minimize the risk of adverse events in CYP2D6 PMs.
  • ||||||||||  Clinical, Journal:  Erector spinae plane block in dogs undergoing hemilaminectomy: A prospective randomized clinical trial. (Pubmed Central) -  Mar 30, 2024   
    This case highlights the importance of considering individual variability in drug metabolism when prescribing medications, particularly opioids such as oxycodone, to ensure optimal therapeutic outcomes and minimize the risk of adverse events in CYP2D6 PMs. The ESP block resulted in a reduced intraoperative opioid consumption compared with the control positive and negative groups.
  • ||||||||||  cyclobenzaprine / Generic mfg.
    Journal:  The rapid recovery study: Cyclobenzaprine's effect on recovery following joint arthroplasty. (Pubmed Central) -  Mar 29, 2024   
    The ESP block resulted in a reduced intraoperative opioid consumption compared with the control positive and negative groups. Postoperative morphine milliequivalents were insignificantly different between cohorts after controlling for pain in all models (base model mean ratio: 1.06, 95% CI (0.87,1.29), p